| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2290 |
| Trial ID | NCT04234061 |
| Disease | Mantle Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Co-treatment | Ibrutinib |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma |
| Year | 2020 |
| Country | Australia |
| Company sponsor | Peter MacCallum Cancer Centre, Australia |
| Other ID(s) | 19/008 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||